scholarly journals Risk–benefit analysis of COVID-19 vaccines — a neurological perspective

Author(s):  
Colleen L. Lau ◽  
Ian Galea
2011 ◽  
Vol 10 (1) ◽  
Author(s):  
Eduardo Massad ◽  
Ben C Behrens ◽  
Francisco AB Coutinho ◽  
Ronald H Behrens

2011 ◽  
Vol 107 (12) ◽  
pp. 1812-1822 ◽  
Author(s):  
Véronique Sirot ◽  
Jean-Charles Leblanc ◽  
Irène Margaritis

Seafood provides n-3 long-chain PUFA (n-3 LC-PUFA), vitamins and minerals, which are essential to maintain good health. Moreover, seafood is a source of contaminants such as methylmercury, arsenic and persistent organic pollutants that may affect health. The aim of the present study was to determine in what quantities seafood consumption would provide nutritional benefits, while minimising the risks linked to food contaminants. Seafood was grouped into clusters using a hierarchical cluster analysis. Those nutrients and contaminants were selected for which it is known that seafood is a major source. The risk–benefit analysis consisted in using an optimisation model with constraints to calculate optimum seafood cluster consumption levels. The goal was to optimise nutrient intakes as well as to limit contaminant exposure with the condition being to attain recommended nutritional intakes without exceeding tolerable upper intakes for contaminants and nutrients, while taking into account background intakes. An optimum consumption level was calculated for adults that minimises inorganic arsenic exposure and increases vitamin D intake in the general population. This consumption level guarantees that the consumer reaches the recommended intake for n-3 LC-PUFA, Se and I, while remaining below the tolerable upper intakes for methylmercury, Cd, dioxins, polychlorobiphenyls, Zn, Ca and Cu. This consumption level, which is approximately 200 g/week of certain fatty fish species and approximately 50 g/week of lean fish, molluscs and crustaceans, has to be considered in order to determine food consumption recommendations in a public health perspective.


2011 ◽  
Vol 17 (1) ◽  
pp. 127-140 ◽  
Author(s):  
Edward V. Loftus ◽  
Scott J. Johnson ◽  
Si-Tien Wang ◽  
Eric Wu ◽  
Parvez M. Mulani ◽  
...  

Anaesthesia ◽  
2021 ◽  
Author(s):  
M. W. Hollmann ◽  
H. Hermanns ◽  
P. Kranke ◽  
M. E. Durieux

Author(s):  
Jeanne Marie Membré ◽  
Sofia Santillana Farakos ◽  
Maarten Nauta

2015 ◽  
Vol 21 (2) ◽  
pp. 6
Author(s):  
Elsa Du Toit ◽  
Eileen Thomas ◽  
Liezl Koen ◽  
Bavi Vythilingum ◽  
Stoffel Grobler ◽  
...  

<p>Selective serotonin reuptake inhibitor (SSRI) antidepressants are considered the primary pharmacological treatment for moderate to severe depression during pregnancy.<span><em> </em></span>Data regarding the safety of their use during pregnancy remain controversial and conflicting. Decisions regarding the prescription of antidepressant treatment are often fraught with concern around potential harmful medication effects on the pregnancy, fetus and infant. Information on potential risks remains extremely varied and inconsistent across sources. This lack of clarity regarding drug safety brings significant uncertainty not only for treating physicians, but also for women seeking information about depression during pregnancy. This review aims to summarise and evaluate the current evidence base and to aid clinicians in performing a risk/benefit analysis for SSRI use during pregnancy and lactation.</p><div> </div>


2006 ◽  
Vol 19 (8) ◽  
pp. 977-981 ◽  
Author(s):  
Ivonne M. C. M. Rietjens ◽  
Gerrit M. Alink

Sign in / Sign up

Export Citation Format

Share Document